Xeris Biopharma Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

• Xeris Biopharma Holdings Inc XERS.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of six analysts for the quarter was for a loss of 3 cents per share. Wall Street expected results to range from -5 cents to -1 cents per share.

• Revenue rose 48.8% to $71.54 million from a year ago; analysts expected $64.58 million.

• Xeris Biopharma Holdings Inc's reported EPS for the quarter was a loss of 1 cent​.

• The company reported a quarterly loss of $1.93 million.

• Xeris Biopharma Holdings Inc shares had risen by 17.6% this quarter and gained 61.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 40.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $7.00, about 21.6% above its last closing price of $5.49

This summary was machine generated from LSEG data August 7 at 05:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)